Coya Therapeutics

Dr. Howard Berman, Ph.D, CEO of Coya Therapeutics Inc (NASDAQ: COYA), were guests on Benzinga’s All Access. Coya is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. The company is currently developing multi-...

Howard Berman, Ph.D., CEO & Chairman of the Board of Coya Therapeutics, Inc. (NASDAQ: COYA), was recently a guest on Benzinga’s All Access. Coya is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells, called...

In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or reverse disease progression. What is clear is the urgency of developing proper treatments for...

Coya Therapeutics (NASDAQ: COYA) has just reported proof of concept data from its trial for COYA 302, a new combination drug for treating amyotrophic lateral sclerosis (ALS). The results for this novel biologic were positive, showing a slowing or even halting of ALS’ progression. There is...

Howard Burman, Ph.D, CEO & Chairman of Coya Therapeutics Inc (NASDAQ: COYA), was a guest on Benzinga’s All Access. Coya is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. The company is currently...

Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India. Through this partnership, Coya will license Dr. Reddy’s biosimilar product, Abatacept, allowing Coya to...

Coya Therapeutics, Inc. (NASDAQ: COYA) recently reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to significantly ameliorate disease progression (stopping progression in all patients at 24 weeks with minimal...

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY), a global pharmaceutical company. Under this agreement, Coya will in-license the proposed Abatacept...

Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field. When the father of company CEO and founder Howard Berman was diagnosed with dementia, Berman became inspired to turn his expertise in neuroscience towards...

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary investigational biologic combination at the 2023 MDA Clinical & Scientific Conference in...

Houston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective proprietary treatments focused on certain neurodegenerative and autoimmune diseases available to more patients, as it announced the expansion of its exclusive worldwide rights for the...